Back to Browse Journals » Research and Reports in Urology » Volume 3

Sipuleucel-T: immunotherapy for advanced prostate cancer

Authors Olson BM, McNeel DG

Published 3 May 2011 Volume 2011:3 Pages 49—60

DOI https://dx.doi.org/10.2147/RRU.S13069

Review by Single-blind

Peer reviewer comments 3

Brian M Olson, Douglas G McNeel
University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI, USA
Abstract: Prostate cancer continues to be one of the most serious afflictions of men of advanced age, remaining the most commonly diagnosed and second leading cause of cancer-related deaths in American men. The treatment options for patients with incurable metastatic, castrate-resistant disease have long focused on various chemotherapeutic approaches, which provide a slight survival benefit while being associated with potentially significant side effects. However, the recent approval of sipuleucel-T has given patients with advanced disease an additional treatment option that has demonstrated benefit without the side effects associated with chemotherapy. Sipuleucel-T is an antigen-presenting cell-based active immunotherapy that utilizes a patient's own immune cells, presumably to activate an antigen-specific immune response against tumor cells. This review focuses on the development and implementation of sipuleucel-T as a therapy for prostate cancer. Specifically, we present some of the issues associated with the management of advanced prostate cancer, the research and development that led to the approval of sipuleucel-T, how the approval of sipuleucel-T could change the clinical management of prostate cancer, and current and future areas of investigation that are being pursued with regard to sipuleucel-T and other treatments for advanced prostate cancer.

Keywords: sipuleucel-T, prostatic acid phosphatase, granulocyte-macrophage colonystimulating factor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Optimal delivery of male breast cancer follow-up care: improving outcomes

Ferzoco RM, Ruddy KJ

Breast Cancer: Targets and Therapy 2015, 7:371-379

Published Date: 23 November 2015

Profile of bevacizumab and its potential in the treatment of cervical cancer

Fisher CM, Schefter TE

OncoTargets and Therapy 2015, 8:3425-3431

Published Date: 19 November 2015

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers

ElHalawani H, Abdel-Rahman O

Therapeutics and Clinical Risk Management 2015, 11:1123-1132

Published Date: 28 July 2015

Clinical utilities of aromatase inhibitors in breast cancer

Chumsri S

International Journal of Women's Health 2015, 7:493-499

Published Date: 6 May 2015

Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma

Brueseke TJ, Tewari KS

Clinical Pharmacology: Advances and Applications 2013, 5:13-19

Published Date: 23 May 2013

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer

D'Arcangelo M, Cappuzzo F

Biologics: Targets and Therapy 2013, 7:61-68

Published Date: 3 March 2013

Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients

Yee AJ, Raje NS

Clinical Interventions in Aging 2012, 7:331-338

Published Date: 3 September 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

How to reduce your cancer risk: mechanisms and myths

Nahleh Z, Bhatti NS, Mal M

International Journal of General Medicine 2011, 4:277-287

Published Date: 8 April 2011

Capecitabine in the management of colorectal cancer

Hirsch BR, Zafar SY

Cancer Management and Research 2011, 3:79-89

Published Date: 24 March 2011